following a full submission assessed under the end of life and orphan equivalent medicine process:
cemiplimab (Libtayo®) is accepted for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
In a phase III study, cemiplimab monotherapy resulted in a significant improvement in overall survival, compared with investigator’s choice of chemotherapy.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- cemiplimab (Libtayo)
- SMC ID:
- SMC2719
- Indication:
As monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
- Pharmaceutical company
- Regeneron Pharmaceuticals Inc
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 February 2025